Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.

MLA

Elurbide, Jasmin, et al. “Identification of PRMT5 as a Therapeutic Target in Cholangiocarcinoma.” Gut, vol. 74, no. 1, Jan. 2025, pp. 116–27. EBSCOhost, https://doi.org/10.1136/gutjnl-2024-332998.

APA

Elurbide, J., Colyn, L., Latasa, M. U., Uriarte, I., Mariani, S., Lopez-Pascual, A., Valbuena, E., Castello-Uribe, B., Arnes-Benito, R., Adan-Villaescusa, E., Martinez-Perez, L. A., Azkargorta, M., Elortza, F., Hanghang Wu, Krawczyk, M., Schneider, K. M., Sangro, B., Aldrighetti, L., Ratti, F., & Gardini, A. C. (2025). Identification of PRMT5 as a therapeutic target in cholangiocarcinoma. Gut, 74(1), 116–127. https://doi.org/10.1136/gutjnl-2024-332998

Chicago

Elurbide, Jasmin, Leticia Colyn, Maria U. Latasa, Iker Uriarte, Stefano Mariani, Amaya Lopez-Pascual, Emiliana Valbuena, et al. 2025. “Identification of PRMT5 as a Therapeutic Target in Cholangiocarcinoma.” Gut 74 (1): 116–27. doi:10.1136/gutjnl-2024-332998.